HIV epidemiology and treatment – 1999

Ocular Immunology and Inflammation

Volumn 7, Issue 42067, 1999, Pages 129-132

  Telenti, Amalio ^a   Bally, Frank ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

CONFERENCE PAPER; DRUG HYPERSENSITIVITY; GASTROINTESTINAL DISEASE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; MORBIDITY; MORTALITY; PANCREATITIS; PERIPHERAL NEUROPATHY;

ANTI-HIV AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE; HIV INFECTIONS; HUMANS; MYCOBACTERIUM INFECTIONS;

EID: 0033392705     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1076/ocii.7.3.129.4005     Document Type: Article

References (16)

1. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338: 853- 86o.
2. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Br Med J 1997; 315: 1194 – 1199.
3. Ledergerber B, Egger M, Erard V, et al. AIDS opportunistic illnesses occurring after initiation of highly active antiretroviral therapy: The Swiss HIV Cohort Study. J Am Med Assoc 1999 (in press).
4. Li TS, Tubiana R, Katlama C, Calvez V, Aitmohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-, disease. Lancet 1998 351: 1682 - 1686.
5. Levy JA. Caution: should we be treating HIV infection early? Lancet 1998; 352: 982 – 983.
6. Carr A, Cooper DA. Gap between biology and reality in AIDS. Lancet 1998; 352: 51V16.
7. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291 – 1295.
8. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-, latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13193 – 13197.
9. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–F58.
10. Henry K, Melroe H, Huebsch J. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328.
11. Ledergerber B, Egger M, Opravil M, et al. Highly active antiretroviral therapy: low rates of clinical disease progression despite high rates of virological failure. Lancet 1999; 353: 863 – 868.
12. Yerly S, Kaiser L, Race EM, Clavel F, Perrin L. Transmission of HIV-, variants resistant to antiretroviral drugs. Lancet 1999; 354: 729 – 733
13. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339: 307 – 311.
14. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. J Am Med Assoc 1998; 280: 78 – 86.
15. Gazzard B, Moyle G. 1998 revision to the British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314 – 316.
16. Swiss Federal Office for Public Health. Antiretroviral therapy for HIV infection in 1998. Bull Swiss Public Health Office 1998; vol. 44.